Department of Hepatogastroenterology, Michallon University Hospital, Grenoble, France.
Colorectal Unit, Department of Surgery, Michallon University Hospital, CS 10 217, 38 043, Grenoble cedex, France.
Tech Coloproctol. 2021 Oct;25(10):1143-1149. doi: 10.1007/s10151-021-02506-8. Epub 2021 Aug 26.
Management of rectovaginal fistula (RVF) in Crohn's disease (CD) is challenging. Available studies are heterogeneous and retrospective, with short-term follow-up. The aim of this study was to assess the overall long-term medico-surgical treatment results in women with RVF due to CD.
A retrospective study was conducted on consecutive patients operated on for RVF in CD from September 1996 to November 2019 at a tertiary teaching hospital. All surgeries were classified as preliminary, closure, or salvage procedures. Primary outcome was fistula remission defined as the combination of fistula closure and no stoma, at least 6 months since last procedure.
Thirty-two patients (median age 34 [range 21-55] years), with a median follow-up of 11.3 years (0-23.7) after first surgery, were included. Altogether, 138 procedures were performed; 36 (26%) preliminary, 80 (58%) closure, and 13 (9%) salvage procedures. RVF remission was obtained in 7/32 patients (22%). At the end of follow-up, a stoma was present in 13/32 patients (41%). The percentage of time on biologics was 86% for patients in remission, versus 36% for the others (p = 0.0057). After univariate analysis, only anti-TNF-α was significantly related to successful closure techniques (p = 0.007).
The RVF remission rate in CD was low in the long term. However, patients underwent a succession of interventions, and the stoma rate was high. Combination of biologics with surgical management was crucial.
克罗恩病(CD)导致的直肠阴道瘘(RVF)的管理具有挑战性。现有的研究具有异质性和回顾性,随访时间较短。本研究旨在评估女性 CD 相关 RVF 的整体长期医学-手术治疗结果。
对 1996 年 9 月至 2019 年 11 月在一家三级教学医院接受 RVF 手术的连续患者进行了回顾性研究。所有手术均分为初步、闭合或挽救手术。主要结局是瘘管缓解,定义为瘘管闭合且无造口,上次手术后至少 6 个月。
共纳入 32 例(中位年龄 34 岁[范围 21-55 岁])患者,第一次手术后中位随访 11.3 年(0-23.7 年)。共进行了 138 次手术;36 次(26%)为初步手术,80 次(58%)为闭合手术,13 次(9%)为挽救手术。32 例患者中有 7 例(22%)获得 RVF 缓解。在随访结束时,13 例(41%)患者存在造口。缓解患者的生物制剂使用率为 86%,而其他患者为 36%(p=0.0057)。单因素分析后,仅抗 TNF-α与成功的闭合技术显著相关(p=0.007)。
CD 患者的 RVF 缓解率长期较低。然而,患者经历了一系列干预,造口率较高。生物制剂联合手术治疗至关重要。